Bevacizumab in recurrent high-grade pediatric gliomas - PubMed (original) (raw)

Bevacizumab in recurrent high-grade pediatric gliomas

Ashwatha Narayana et al. Neuro Oncol. 2010 Sep.

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown promise in treating recurrent adult high-grade glioma (HGG). However, there is very little data on recurrent or progressive pediatric HGG treated with bevacizumab. We report the results of a single institution experience using bevacizumab and irinotecan in children who relapsed or progressed following standard therapy. Twelve pediatric patients with recurrent or progressive HGG received bevacizumab at 10 mg/kg every 2 weeks with irinotecan at 125 mg/m(2). Magnetic resonance imaging (MRI) was performed prior to therapy and every 8 weeks subsequently. Ten patients had supratentorial HGG; 2 had DIPG. Radiological responses were defined according to MacDonald's criteria. Progression-free survival (PFS), overall survival (OS), and toxicities were analyzed. Ten (83.3%) patients tolerated bevacizumab without serious toxicity. Therapy was discontinued in 1 patient because of anaphylaxis. Another patient developed grade III delayed wound healing and deep vein thrombosis. Two patients (16.7%) experienced a partial response after the first MRI. No complete radiographic responses were seen. Stable disease was noted in 4 (33.3%) patients. The median PFS and OS were 2.25 and 6.25 months, respectively. A diffuse invasive recurrence pattern was noted in 5 (45.5%) patients. Treatment tolerance, toxicity, and recurrence profiles were comparable to adult HGG patients treated with bevacizumab. However, the radiological response rate, response duration, and survival appeared inferior in pediatric patients. Genetic differences in pediatric gliomas might account for this difference.

PubMed Disclaimer

Figures

Fig. 1.

Fig. 1.

Four-year-old girl with recurrent anaplastic astrocytoma treated with bevacizumab and irinotecan. Image sets 1 and 2 represent T2/FLAIR and contrast-enhanced MRI sequences, respectively. Series A and B represent MRI images taken 2 weeks prior to treatment and 8 weeks after the start of treatment. Series C shows local tumor progression 5 months after the start of treatment.

Fig. 2.

Fig. 2.

Progression-free survival (PFS) and overall survival (OS).

Similar articles

Cited by

References

    1. Halperin E, Constine L, Tarbell N, Kun L. Pediatric Radiation Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
    1. Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics. 2009;6(3):570–586. doi:10.1016/j.nurt.2009.04.006. - DOI - PMC - PubMed
    1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–2342. doi:10.1056/NEJMoa032691. - DOI - PubMed
    1. Traina TA, Rugo HS, Dickler M. Bevacizumab for advanced breast cancer. Hematology/Oncology Clinics of North America. 2007;21(2):303–319. doi:10.1016/j.hoc.2007.03.006. - DOI - PubMed
    1. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized Phase II Trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184–2191. doi:10.1200/JCO.2004.11.022. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources